Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
April 15, 2024
Article published by Morning Star
Praxis Precision Medicines, Inc. provided an update on its Phase 2a proof of concept study evaluating PRAX-628 in epilepsy patients. The study used photo paroxysmal response (PPR) to stimulate seizure activity and measured changes in electroencephalogram (EEG) signatures as an indicator of anti-seizure efficacy of the potential new treatment for epilepsy. Patient EEG signatures were assessed at defined measurement points over a 24-hour period after receiving placebo or PRAX-628, and results were compared to baseline. In the study, patients were treated with 15mg or 45mg of PRAX-628. Following treatment with PRAX-628, there was a significant reduction in the number of PPR events in both groups with those in the 45 mg group showing no seizure events in response to photic stimulation. “With such a clear response, we have advanced our planning of the focal epilepsy efficacy study for PRAX-628, expected to begin in the second half of 2024. We extend our thanks to the patients who participated in this PPR study,” said Marcio Souza, president and chief executive officer of Praxis.